Selling, General, and Administrative Costs: Verona Pharma plc vs ACADIA Pharmaceuticals Inc.

SG&A Expenses: ACADIA vs. Verona Pharma (2014-2023)

__timestampACADIA Pharmaceuticals Inc.Verona Pharma plc
Wednesday, January 1, 2014327480001802274
Thursday, January 1, 2015908040002512761
Friday, January 1, 20161864560002894488
Sunday, January 1, 20172550620008096274
Monday, January 1, 20182657580007985229
Tuesday, January 1, 20193256380008994597
Wednesday, January 1, 202038866100029772000
Friday, January 1, 202139602800033907000
Saturday, January 1, 202236909000026579000
Sunday, January 1, 202340246600049868547
Loading chart...

Unleashing insights

A Tale of Two Biopharma Giants: SG&A Expenses Over Time

In the competitive world of biopharmaceuticals, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Verona Pharma plc and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Over this period, ACADIA Pharmaceuticals consistently outspent Verona Pharma, with its SG&A expenses peaking at approximately $402 million in 2023, a staggering 1,200% increase from 2014. In contrast, Verona Pharma's expenses grew more modestly, reaching nearly $50 million in 2023, marking a 2,670% rise from its 2014 figures. This stark difference highlights ACADIA's aggressive expansion strategy compared to Verona's more conservative approach. Understanding these trends offers valuable insights into each company's operational priorities and market strategies, providing a window into their future growth trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025